Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial

Abstract Background Cardiogenic shock (CS) occurs in 5–10% of patients with acute myocardial infarction (AMI), and the condition is associated with a 30-day mortality rate of up to 50%. Most of the AMI patients are in SCAI SHOCK stage B upon hospital arrival, but some of these patients will progress...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarah Louise Duus Holle, Joakim Bo Kunkel, Christian Hassager, Redi Pecini, Sebastian Wiberg, Pernille Palm, Lene Holmvang, Lia Evi Bang, Jesper Kjærgaard, Jakob Hartvig Thomsen, Thomas Engstrøm, Jacob Eifer Møller, Jacob Thomsen Lønborg, Helle Søholm, Martin Frydland
Format: Article
Language:English
Published: BMC 2024-10-01
Series:Trials
Subjects:
Acute myocardial infarction
Cardiogenic shock
Hemodynamic
Dobutamine
Inotropy
Neurohormonal activation
Online Access:https://doi.org/10.1186/s13063-024-08567-y
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13063-024-08567-y

Similar Items